skip to Main Content

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Newsfeed image, light gray text on dark gray background
Patients with TP53-mutated pancreatic ductal adenocarcinoma, or PDAC, may respond better to adjuvant treatment with the chemotherapy drug gemcitabine (Gemzar) than patients with TP53-wildtype tumors, according to a new study published in Clinical Cancer Research.

Although the study’s authors noted that their findings will need to be validated through further research, the potential for TP53 to serve as a predictive and prognostic biomarker for PDAC indicates the rise of precision medicine in a patient population that has previously seen limited treatment advances. Read more . . . 

Back To Top